Abstract
Hepatopulmonary syndrome (HPS) is a pulmonary vascular disorder characterized by altered gas exchange due to intrapulmonary vascular dilatations occurring in the setting of hepatic dysfunction, usually with portal hypertension. The hallmark of HPS is hypoxemia and intrapulmonary shunting of blood, with the diagnosis being made based on a constellation of clinical, laboratory, and imaging data. HPS is defined by: (1) the presence of liver disease, usually with cirrhosis and portal hypertension; (2) abnormal arterial oxygenation, with an alveolar–arterial gradient ≥ 15 mmHg (or ≥ 20 mmHg in patients ≥ 65 years of age) or an arterial partial pressure of oxygen less than 80 mmHg while breathing room air based on arterial blood gas sampling; (3) evidence of intrapulmonary shunting on transthoracic echocardiography with injection of agitated saline; and (4) the absence of cardiopulmonary disease that would otherwise cause hypoxemia. HPS has important clinical implications in regard to impaired patient quality of life and increased posttransplant mortality. There are currently no treatments approved for the treatment of HPS, and the only widely accepted curative option for HPS remains liver transplantation. Resolution of hypoxemia and normalization of pulmonary function have been well documented after transplantation in patients with HPS. Posttransplant outcomes are very good for transplant recipients with HPS, although there are data to suggest worse outcomes in those with more severe hypoxemia.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Krowka MJ, Wiseman GA, Burnett OL, Spivey JR, Therneau T, Porayko MK, et al. Hepatopulmonary syndrome: a prospective study of relationships between severity of liver disease, PaO(2) response to 100 % oxygen, and brain uptake after (99m)Tc MAA lung scanning. Chest. 2000;118(3):615–24.
Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology. 2005;41(5):1122–9.
Krowka MJ, Fallon MB. Liver transplantation for hepatopulmonary syndrome (HPS): what is the MESSAGE? Am J Transplant. 2008;8(5):911–2.
Krowka MJ, Mandell MS, Ramsay MA, Kawut SM, Fallon MB, Manzarbeitia C, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl. 2004;10(2):174–82.
Krowka MJ. Hepatopulmonary syndrome versus portopulmonary hypertension: distinctions and dilemmas. Hepatology. 1997;25(5):1282–4.
Rodriquez-Roisin R, Krowka MJ, Herve P, Fallon MB, Committee ERSTF-PS. Highlights of the ERS task force on pulmonary-hepatic vascular disorders (PHD). J Hepatol. 2005;42(6):924–7.
Fallon MB, Krowka MJ, Brown RS, Trotter JF, Zacks S, Roberts KE, et al. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology. 2008;135(4):1168–75.
Schenk P, Schoniger-Hekele M, Fuhrmann V, Madl C, Silberhumer G, Muller C. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology. 2003;125(4):1042–52.
Abrams GA, Sanders MK, Fallon MB. Utility of pulse oximetry in the detection of arterial hypoxemia in liver transplant candidates. Liver Transpl. 2002;8(4):391–6.
Arguedas MR, Abrams GA, Krowka MJ, Fallon MB. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology. 2003;37(1):192–7.
Fuhrmann V, Madl C, Mueller C, Holzinger U, Kitzberger R, Funk GC, et al. Hepatopulmonary syndrome in patients with hypoxic hepatitis. Gastroenterology. 2006;131(1):69–75.
Regev A, Yeshurun M, Rodriguez M, Sagie A, Neff GW, Molina EG, et al. Transient hepatopulmonary syndrome in a patient with acute hepatitis A. J Viral Hepat. 2001;8(1):83–6.
Teuber G, Teupe C, Dietrich CF, Caspary WF, Buhl R, Zeuzem S. Pulmonary dysfunction in non-cirrhotic patients with chronic viral hepatitis. Eur J Intern Med. 2002;13(5):311–8.
Schraufnagel DE, Kay JM. Structural and pathologic changes in the lung vasculature in chronic liver disease. Clin Chest Med. 1996;17(1):1–15.
Schraufnagel DE, Malik R, Goel V, Ohara N, Chang SW. Lung capillary changes in hepatic cirrhosis in rats. Am J Physiol. 1997; 272(1 Pt 1):L139–47.
Gomez FP, Barbera JA, Roca J, Burgos F, Gistau C, Rodriguez-Roisin R. Effects of nebulized N(G)-nitro-L-arginine methyl ester in patients with hepatopulmonary syndrome. Hepatology. 2006;43(5):1084–91.
Gomez FP, Martinez-Palli G, Barbera JA, Roca J, Navasa M, Rodriguez-Roisin R. Gas exchange mechanism of orthodeoxia in hepatopulmonary syndrome. Hepatology. 2004;40(3):660–6.
Rodriguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome—a liver-induced lung vascular disorder. N Engl J Med. 2008;358(22):2378–87.
Sorafenib for Hepatopulmonary Syndrome. Sorafenib for Hepatopulmonary Syndrome. http://clinicaltrials.gov/ct2/show/NCT02021929.
Fritz JS, Fallon MB, Kawut SM. Pulmonary vascular complications of liver disease. American Journal of Respiratory and Critical Care Medicine. 2013;187(2):133–43.
Abrams GA, Nanda NC, Dubovsky EV, Krowka MJ, Fallon MB. Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. Gastroenterology. 1998;114(2):305–10.
Gupta LB, Kumar A, Jaiswal AK, Yusuf J, Mehta V, Tyagi S, et al. Pentoxifylline therapy for hepatopulmonary syndrome: a pilot study. Arch Intern Med. 2008;168(16):1820–3.
Tanikella R, Philips GM, Faulk DK, Kawut SM, Fallon MB. Pilot study of pentoxifylline in hepatopulmonary syndrome. Liver Transpl. 2008;14(8):1199–203.
De BK, Dutta D, Pal SK, Gangopadhyay S, Das Baksi S, Pani A. The role of garlic in hepatopulmonary syndrome: a randomized controlled trial. Can J Gastroenterol. 2010;24(3):183–8.
Najafi SM, Kianifar HR, Kianee A, Khatami G. Effect of oral garlic on arterial oxygen pressure in children with hepatopulmonary syndrome. World J Gastroenterol. 2006;12(15):2427–31.
Gupta S, Castel H, Rao RV, Picard M, Lilly L, Faughnan ME, et al. Improved survival after liver transplantation in patients with hepatopulmonary syndrome. Am J Transplant. 2010;10(2):354–63.
Iyer VN, Swanson KL, Cartin-Ceba R, Dierkhising RA, Rosen CB, Heimbach JK, et al. Hepatopulmonary syndrome: favorable outcomes in the MELD exception era. Hepatology. 2012;57:2427–35
Goldberg DS, Krok K, Batra S, Trotter JF, Kawut SM, Fallon MB. Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database. Gastroenterology. 2014; 146:1256–1265.
Benitez C, Arrese M, Jorquera J, Godoy I, Contreras A, Loyola S, et al. Successful treatment of severe hepatopulmonary syndrome with a sequential use of TIPS placement and liver transplantation. Ann Hepatol. 2009;8(1):71–4.
Nistal MW, Pace A, Klose H, Benten D, Lohse AW. Hepatopulmonary syndrome caused by sarcoidosis of the liver treated with transjugular intrahepatic portosystemic shunt. Thorax. 2013;68(9):889–90.
Wallace MC, James AL, Marshall M, Kontorinis N. Resolution of severe hepato-pulmonary syndrome following transjugular portosystemic shunt procedure. BMJ Case Rep. 2012;2012.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Goldberg, D., Fallon, M. (2015). Hepatopulmonary Syndrome. In: Keaveny, A., Cárdenas, A. (eds) Complications of Cirrhosis. Springer, Cham. https://doi.org/10.1007/978-3-319-13614-1_18
Download citation
DOI: https://doi.org/10.1007/978-3-319-13614-1_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-13613-4
Online ISBN: 978-3-319-13614-1
eBook Packages: MedicineMedicine (R0)